ArticlePLoS neglected tropical diseases2025
The impact and cost of a new rapid diagnostic test for school-based prevalence mapping and monitoring and evaluation surveys of schistosomiasis: A modelling study.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Economic Evaluation of Multi-Objective Schistosomiasis Control Through Systemic Causality: Theoretical Advances and Governance Implications.Tropical medicine and infectious disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIn endemic communities where the prevalence of Schistosomiasis is ≥ 10%, annual preventive chemotherapy is recommended. Traditional sampling methods determine infection prevalence through district-level surveys in school-aged-children (SAC). Recently, an alternative sampling strategy-the Schistosomiasis Practical and Precision Assessment (SPPA) protocol-was developed to aid in targeting treatment to the sub-district level. A prototype circulating anodic antigen rapid diagnostic test (CAA RDT) could avoid the pitfalls associated with current microscopy techniques and therefore be better suited to support precision-mapping. METHODOLOGY: We modelled the ability of a CAA RDT to correctly classify sub-district prevalence above or below the 10% threshold in simulated districts under alternative sampling strategies. Each district (10 sub-districts/district) had varying mean prevalence and prevalence distributions. Test sensitivity (60-100%) and specificity (95-100%) of the CAA RDT was varied. We then determined the associated survey costs for prevalence mapping or monitoring and evaluation for each sampling strategy using the CAA RDT compared to microscopy.
resultsThe CAA RDT cost/SAC was US$12.14, which was similar to Kato-Katz (US$13.23/SAC) using traditional sampling. Sampling with the CAA RDT cost the least when conducting SPPA sampling or M&E, or when both Kato-Katz and urine filtration were required. High specificity of the CAA RDT was a key determinant of performance and a test with 100% specificity and 85% sensitivity correctly classified the most sub-districts (87%) under SPPA sampling. SPPA sampling generally led to less under- and overtreatment of sub-districts compared to traditional sampling.
conclusionsA CAA RDT with high specificity will lead to similar treatment success at lower costs, under either sampling strategy, as compared to Kato-Katz and urine filtration. The CAA RDT could be a valuable diagnostic tool for determining schistosomiasis prevalence and could better support precision mapping strategies through reduced costs, thereby improving mass drug administration and aiding programmes to eliminate schistosomiasis as a public health problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.